



ANDVsMgp1 blocking peptide (CDBP5055)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Conjugate	Unconjugated
Applications	Used as a blocking peptide in immunoblotting applications.
Format	Liquid
Concentration	200 µg/mL
Size	0.05 mg
Preservative	None
Storage	-20°C

BACKGROUND

Introduction	HCPS due to the Andes virus infection, has a case fatality percentage of about 25-35% in Argentina and of 37% in Chile. ANDV, lineage ANDV-Sout, is the only hantavirus for which a person-to-person transmission has been described. Several ANDV strains are co-circulating in Argentina, e.g. Bermejo, Lechiguana, Maciel, Oran and Pergamino, whereas HCPS cases were also reported in Bolivia, Brazil, Paraguay and Uruguay. Only for Chile and Argentina can they be strictly associated with ANDV. In Argentina and Chile, the long-tailed rice rat, Oligoryzomys longicaudatus, and other species of the genus Oligoryzomys represent the reservoir for ANDV. Another unique characteristic of ANDV is the availability of an animal model. ANDV causes lethal disease in the Syrian Hamster that closely models the course of disease progression in humans, including a rapid progression from first symptoms to death, including fluid in the pleural cavity and the histopathology of the lungs and spleen. Lethality of ANDV in hamsters is not true of all HCPS viruses, as challenge with Sin Nombre virus shows no symptoms of disease. The availability of this model allows for the study of various drugs and other treatments that may have an impact on the treatment of all HCPS-causing hantavirus infections.
---------------------	---

Keywords

ANDVsMgp1; G1 and G2 surface glycoprotein precursor
